Status:
COMPLETED
Gene Polymorphisms of Corticosteroid-induced Ocular Hypertension
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Corticosteroid Induced Ocular Hypertension/Glaucoma
Eligibility:
All Genders
18+ years
Brief Summary
Glaucoma is one of the most prevalent eye diseases and the second most common cause of blindness worldwide. The most common form is primary open angle glaucoma (POAG). Glaucoma is a slowly progressing...
Eligibility Criteria
Inclusion
- Use of corticosteroids:
- Patients treated with Ozurdex (an intravitreal dexamethasone implant
- Patients treated with subconjunctival Triamcinolone/ Celestone injections
- Patients treated with corticosteroids after a corneal surgery
- Patients treated with corticosteroids after a refractive surgery
- Patients treated with corticosteroids after a cataract surgery
- Patients treated with corticosteroids for macular edema
- Patients exposed to corticosteroids for other diseases such as uveitis
- When using topical corticosteroids, time of use \> 3 months
- Age \> 18 year and mentally competent
- Patient from the Maastricht University Medical Centre+ (MUMC+), the Netherlands
Exclusion
- Age \< 18 year
- Mentally not able to participate or give permission
- Not able to communicate in Dutch
- Patients with a type of uveitis that might cause a decrease of the IOP
- When using topical corticosteroids, time of use \< 3 months.
Key Trial Info
Start Date :
September 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2020
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT03250819
Start Date
September 13 2017
End Date
May 1 2020
Last Update
June 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Eye Clinic Maastricht, Maastricht UMC+
Maastricht, Limburg, Netherlands, 6229 HX